These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 19885299)

  • 1. Alzheimer's disease is type 3 diabetes-evidence reviewed.
    de la Monte SM; Wands JR
    J Diabetes Sci Technol; 2008 Nov; 2(6):1101-13. PubMed ID: 19885299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
    Steen E; Terry BM; Rivera EJ; Cannon JL; Neely TR; Tavares R; Xu XJ; Wands JR; de la Monte SM
    J Alzheimers Dis; 2005 Feb; 7(1):63-80. PubMed ID: 15750215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.
    de la Monte SM
    Drugs; 2012 Jan; 72(1):49-66. PubMed ID: 22191795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators.
    Jayaraj RL; Azimullah S; Beiram R
    Saudi J Biol Sci; 2020 Feb; 27(2):736-750. PubMed ID: 32210695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking insulin with Alzheimer's disease: emergence as type III diabetes.
    Ahmed S; Mahmood Z; Zahid S
    Neurol Sci; 2015 Oct; 36(10):1763-9. PubMed ID: 26248483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain metabolic dysfunction at the core of Alzheimer's disease.
    de la Monte SM; Tong M
    Biochem Pharmacol; 2014 Apr; 88(4):548-59. PubMed ID: 24380887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.
    Lester-Coll N; Rivera EJ; Soscia SJ; Doiron K; Wands JR; de la Monte SM
    J Alzheimers Dis; 2006 Mar; 9(1):13-33. PubMed ID: 16627931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease.
    de la Monte SM; Tong M
    J Alzheimers Dis; 2009; 17(4):817-25. PubMed ID: 19542621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes.
    Michailidis M; Moraitou D; Tata DA; Kalinderi K; Papamitsou T; Papaliagkas V
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and Alzheimer's Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?
    Potenza MA; Sgarra L; Desantis V; Nacci C; Montagnani M
    Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease.
    Arab L; Sadeghi R; Walker DG; Lue LF; Sabbagh MN
    Curr Neuropharmacol; 2011 Dec; 9(4):693-705. PubMed ID: 22654727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease.
    Wakabayashi T; Yamaguchi K; Matsui K; Sano T; Kubota T; Hashimoto T; Mano A; Yamada K; Matsuo Y; Kubota N; Kadowaki T; Iwatsubo T
    Mol Neurodegener; 2019 Apr; 14(1):15. PubMed ID: 30975165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia.
    Folch J; Ettcheto M; Busquets O; Sánchez-López E; Castro-Torres RD; Verdaguer E; Manzine PR; Poor SR; García ML; Olloquequi J; Beas-Zarate C; Auladell C; Camins A
    Pharmaceuticals (Basel); 2018 Jan; 11(1):. PubMed ID: 29382127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer's disease.
    Rad SK; Arya A; Karimian H; Madhavan P; Rizwan F; Koshy S; Prabhu G
    Drug Des Devel Ther; 2018; 12():3999-4021. PubMed ID: 30538427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.
    de la Monte SM; Wands JR
    J Alzheimers Dis; 2005 Feb; 7(1):45-61. PubMed ID: 15750214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.
    Pardeshi R; Bolshette N; Gadhave K; Ahire A; Ahmed S; Cassano T; Gupta VB; Lahkar M
    Psychoneuroendocrinology; 2017 Sep; 83():159-171. PubMed ID: 28624654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease.
    de la Monte SM; Tong M; Lester-Coll N; Plater M; Wands JR
    J Alzheimers Dis; 2006 Sep; 10(1):89-109. PubMed ID: 16988486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes.
    de la Monte SM
    Adv Exp Med Biol; 2019; 1128():45-83. PubMed ID: 31062325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder.
    Kshirsagar V; Thingore C; Juvekar A
    Metab Brain Dis; 2021 Jan; 36(1):67-83. PubMed ID: 32986168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.